SYT-510

SYT-510
Clinical data
Other namesSYT510
Routes of
administration		Oral
Drug classSelective endocannabinoid reuptake inhibitor (SERI)

SYT-510 is a selective endocannabinoid reuptake inhibitor (SERI) which is under development for the treatment of psychiatric disorders, anxiety disorders, mood disorders, and traumatic stress disorders. It is currently being developed by a pharmaceutical company called Synendos Therapeutics.

SERIs have been shown to both mildly and selectively increase levels of endocannabinoids such as anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) via inhibition of a newly identified biological target. In September 2025, Synendos reported the successful completion of Phase 1 clinical trials in healthy volunteers, paving the way for the start of Phase 2a clinical study in Generalized Anxiety Disorder (GAD).

See also

References

  1. 1 2 3 4 "Delving into the Latest Updates on SYT-510 with Synapse". Synapse. 4 August 2024. Retrieved 15 August 2024.
  2. 1 2 3 4 "SYT 510". AdisInsight. 22 January 2024. Retrieved 15 August 2024.
  3. 1 2 3 4 Kuntz, Leah (24 September 2025). "SYT-510: First-in-Class Inhibitor Targets Endocannabinoid System to Improve Mental Health Outcomes". Psychiatric Times. Retrieved 26 April 2026.
  4. 1 2 3 Gertsch J, Chicca A (July 2024). "CNS Drug Discovery in Academia: Where Basic Research Meets Innovation". ChemBioChem e202400397. doi:10.1002/cbic.202400397. PMID 38958639. Five years after incorporation, Synendos Therapeutics has completed non-clinical development of the [selective endocannabinoid reuptake inhibitor (SERI)] drug candidate SYT-510 and has initiated Phase 1 clinical development in healthy volunteers, marking the significant transition into a clinical stage biotech company. The mission of Synendos is to develop breakthrough safe and effective therapies for neurological and neuropsychiatric disorders through modulation of the [endocannabinoid system (ECS)] with SERIs to enable restoration of the natural functioning of the brain.
  5. 1 2 3 Synendos Therapeutics, AG (18 January 2024). "Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510". PR Newswire. Retrieved 15 August 2024.
  6. ↑ Synendos Therapeutics, AG (2026-05-20). "Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder". GlobeNewswire News Room. Retrieved 2026-06-18.